We regularly tell you about Novo Nordisk, the new Scandinavian darling, which is riding the wave of American enthusiasm for its weight-loss drugs. Propelled recently by the encouraging results of Wegovy, its flagship anti-obesity treatment, in reducing cardiovascular accidents in overweight adults (with a 17% rise in a single day), the manufacturer's capitalization has gained a third since the start of the year.

And this spectacular rise is not without consequences for the small state. According to several economists, it has even led to a drop in interest rates in the country. The success of weight-loss products has led to a remarkable influx of dollars converted into kroner, increasing the value of the Nordic currency against the euro, the currency on which Denmark's central bankers are aligned. In response, Danmarks Nationalbank maintained rates below those of the ECB. Exports of pharmaceuticals are also expected to benefit the local economy and employment.

But isn't this influence on the country and its financial center disproportionate? Observers are quick to compare the situation with that of Nokia, the former star of the Finnish markets, whose decline precipitated the economic stagnation of its home nation.

Will there even be a decline? With obesity becoming a major issue in both Western and developing countries, the Group can count on a steadily growing market. Drug sales are expected to earn the group over $6 billion this year, and an estimated $15 billion by 2027.

Today, Novo Nordisk is the continent's second-largest listed company, and its logo is the Egyptian mythological bull Apis, a symbol of power and fertility. Let's hope this choice is a good omen. (Oh yes, and let's not forget that the historic symbol of Copenhagen is the Little Mermaid, who on her rock welcomes sailors at the entrance to the Danish harbor).

By Amandine Victor